Cardinal Health - Q3 Fiscal 2026 Earnings Analysis
Cardinal Health delivered a strong Q3 FY2026, with non-GAAP diluted EPS surging 35% year-over-year to $3.17 and revenue climbing 11% to $60.9 billion, driven by branded and specialty pharmaceutical growth. A $184 million goodwill impairment on the Navista & ION oncology platform weighed on GAAP results, while tariff headwinds continued to pressure the GMPD segment.
Performance Highlights
Cardinal Health reported Q3 FY2026 revenue of $60.9 billion, an 11% year-over-year increase that outpaced expectations, alongside non-GAAP diluted EPS of $3.17, up 35% from $2.35 in the prior-year quarter. GAAP diluted EPS declined 20% to $1.69, distorted by a $184 million goodwill impairment charge on the Navista & ION oncology reporting unit and $112 million in acquisition-related compensation costs tied to The Specialty Alliance.
The dominant operating driver was the Pharmaceutical and Specialty Solutions segment, where profit rose 18% to $784 million on the back of branded and specialty pharmaceutical demand, generics program performance, and early contributions from MSO platform acquisitions including Solaris Health, GI Alliance, and Urology America. The Other segment also outperformed, with profit up 34% to $179 million, while GMPD segment profit fell sharply to just $25 million, down 36%, due to approximately $200 million in cumulative IEEPA tariff costs paid through quarter-end.
Management Outlook and Forward Catalysts
Management's capital deployment posture — $1.9 billion for Solaris Health, $1.0 billion in share repurchases, and $1.0 billion in new debt issuance — signals a conviction-driven build-out of the specialty physician practice management platform, with The Specialty Alliance now spanning more than 750 providers across urology and gastroenterology. Non-GAAP operating earnings of $2.7 billion through nine months, up 30%, suggest management believes the MSO integration runway can sustain elevated earnings growth into FY2027.
The central investor debate heading into Q4 centers on whether GMPD can stabilize as IEEPA tariff refunds — potentially recoverable but delayed beyond Phase 1 CBP processing — materialize, and whether the Navista & ION impairment signals deeper structural risk in the oncology MSO thesis. Bulls will focus on specialty pharma volume, GLP-1 tailwinds, and MSO scale; bears will watch tariff resolution timing, rising interest expense up 91% year-over-year to $269 million, and execution risk at Navista.
Adjusted EPS vs. consensus breakdown — primary performance driver, segment revenue contribution, and gross margin trajectory relative to prior guidance...
Segment-by-segment revenue analysis, margin profile, and management commentary on demand trajectory vs. consensus range expectations...
Forward guidance implications for the sector, supply chain read-throughs, and investment implications for the broader competitive landscape...